Bullish Case: MPLX sits at $60.15 with a 7.6% yield backed by 1.3x coverage and 13 years of raises; Q3 earnings due mid-quarter with BANGL/Blackcomb/Delaware projects ramping into Q4-2027 EBITDA acceleration. Helium's density (trace_0) peaks at $60 (0.2917) vs market 0.2932, nearly identical, but Helium's downside tail at $55 (0.0393) is far thinner than market's 0.066, implying less downside risk than market prices. Term structure is flat-to-contangoed; Helium IV (18.0/15.5/14.1) sits well below market IV (23.9/19.2/16.8) at the Nov/Dec/Jan expiries, suggesting overpriced near-dated premiums if no catalyst materializes.

Bearish Case: Helium's AI forecast reads +3.05% but realized correlation is only 0.1, weak evidentiary support. Market IV exceeds Helium IV across the entire term structure (23.9 vs 18.0 at Nov 21), a signal the market knows something Helium's model may underweight. Deep-OTM put IVs (Nov 30P at 200%, 35P at 185%) show extreme tail fear. Nov 20th expiry lands only 21 days out with heavy put open interest at 57.5/60 strikes, implying event hedging around Q3 distribution timing. A commodity/credit headline could compress the 3.0x book multiple quickly.

Potential Outcomes: Scenario weights:

1. Rangebound $58–$62 (40%) — flat trend, IV decay; falsify if Nov put IV rises above 25%.

2. Modest rally +5–10% to $63–$66 (30%) — calls traded 83% more than puts, Q3 DCF beat; falsify if call IV cools with flat spot.

3. Correction -5 to -10% to $54–$57 (20%) — Helium-vs-market IV gap and rich tail skew warn downside risk is underpriced; falsify if spot holds above $60 through Dec expiry.

4. Tail shock ≤ -12% below $53 (10%) — extreme deep-put IVs imply real tail demand; falsify if Jan 15 2027 40P IV normalizes below 30%.

October 31, 2026